Find clinical trials for Pancreatic Cancer in San Francisco, CA
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near San Francisco, CA, USA:
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic...
Phase 1
San Francisco, California, United States and 1 other location
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
San Francisco, California, United States and 15 other locations
in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreat...
Phase 1, Phase 2
San Francisco, California, United States and 11 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
San Francisco, California, United States and 38 other locations
with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors...
Phase 2
San Francisco, California, United States and 2 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
San Francisco, California, United States and 41 other locations
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...
Phase 2
San Jose, California, United States and 71 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec ...
Phase 1, Phase 2
Stanford, California, United States and 10 other locations
intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer...
Phase 1, Phase 2
San Francisco, California, United States and 6 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
San Francisco, California, United States and 65 other locations
Clinical trials
Research sites
Resources
Legal